$200 million matching program for Good Days Retinal Fund backed by Regeneron founders Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos

Regeneron Pharmaceuticals’ new $200 million donation matching initiative for the Good Days Retinal Fund is being led directly by the company’s two founding principals, Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos. Their hands-on involvement underscores the company’s longstanding commitment to patient access and innovative philanthropy.

Dr. Leonard S. Schleifer, Regeneron’s co-founder, President, and CEO, has championed the vision of leveraging science and corporate resources to improve patient outcomes since the company’s inception. Schleifer’s leadership has been instrumental in shaping Regeneron’s ethos of direct engagement in both scientific and community initiatives.

Dr. George D. Yancopoulos, co-founder, President, and Chief Scientific Officer, is equally central to the program. Yancopoulos, recognized for his groundbreaking work in drug discovery and development, has consistently advocated for initiatives that bridge scientific innovation and real-world patient needs.

As a principal inventor of Regeneron’s foundational technologies and therapies for vision-threatening diseases, Yancopoulos is personally invested in expanding access to sight-saving treatments.

Both Schleifer and Yancopoulos are not only the architects of Regeneron’s scientific achievements but also the driving force behind its philanthropic strategies.

Their direct oversight of the $200 million matching program ensures that the initiative aligns with Regeneron’s core values of scientific rigor, patient focus, and broad community impact.

The matching program, under their guidance, is designed to double the impact of donations, enabling Good Days to provide even greater assistance to patients facing financial barriers to critical retinal therapies.

Their personal leadership in this effort reflects the unique, founder-driven culture at Regeneron, where the principals’ involvement extends from the laboratory to the boardroom and into community partnerships.